Investigating a new option for CF patients with MRSA
Learn MoreFind a SiteAVAIL is a Phase 3 clinical study of the investigational drug AeroVanc for persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung infection in cystic fibrosis patients
